1. Home
  2. LEGN vs CADE Comparison

LEGN vs CADE Comparison

Compare LEGN & CADE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • CADE
  • Stock Information
  • Founded
  • LEGN 2014
  • CADE 1876
  • Country
  • LEGN United States
  • CADE United States
  • Employees
  • LEGN N/A
  • CADE N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • CADE Major Banks
  • Sector
  • LEGN Health Care
  • CADE Finance
  • Exchange
  • LEGN Nasdaq
  • CADE Nasdaq
  • Market Cap
  • LEGN 6.0B
  • CADE 6.3B
  • IPO Year
  • LEGN 2020
  • CADE N/A
  • Fundamental
  • Price
  • LEGN $32.66
  • CADE $35.66
  • Analyst Decision
  • LEGN Strong Buy
  • CADE Buy
  • Analyst Count
  • LEGN 13
  • CADE 11
  • Target Price
  • LEGN $80.62
  • CADE $37.55
  • AVG Volume (30 Days)
  • LEGN 1.3M
  • CADE 1.2M
  • Earning Date
  • LEGN 03-10-2025
  • CADE 01-22-2025
  • Dividend Yield
  • LEGN N/A
  • CADE 2.81%
  • EPS Growth
  • LEGN N/A
  • CADE 74.38
  • EPS
  • LEGN N/A
  • CADE 3.51
  • Revenue
  • LEGN $520,183,000.00
  • CADE $1,271,175,000.00
  • Revenue This Year
  • LEGN $120.36
  • CADE N/A
  • Revenue Next Year
  • LEGN $67.91
  • CADE $5.81
  • P/E Ratio
  • LEGN N/A
  • CADE $55.32
  • Revenue Growth
  • LEGN 122.96
  • CADE N/A
  • 52 Week Low
  • LEGN $30.17
  • CADE $24.99
  • 52 Week High
  • LEGN $70.13
  • CADE $40.20
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 41.28
  • CADE 53.22
  • Support Level
  • LEGN $30.17
  • CADE $35.16
  • Resistance Level
  • LEGN $37.92
  • CADE $36.29
  • Average True Range (ATR)
  • LEGN 2.07
  • CADE 0.93
  • MACD
  • LEGN 0.12
  • CADE 0.20
  • Stochastic Oscillator
  • LEGN 32.13
  • CADE 80.79

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About CADE Cadence Bank

Cadence Bank is a bank based in the United States. The operating segments are Corporate Banking segment focuses on C&I, business banking, and commercial real estate lending to clients in the geographic footprint, Community Banking segment provides a broad range of banking services through the branch network to serve the needs of community businesses and individual consumers in the geographic footprint, Mortgage segment includes mortgage banking activities of originating mortgage loans, selling mortgage loans in the secondary market and servicing the mortgage loans, Banking Services segment offers individuals, businesses, governmental institutions, and non-profit entities a widerange of solutions to help protect, grow, and transfer wealth, General Corporate and Other segment.

Share on Social Networks: